By Adjunct Professor Michael Leonard Friedlander

Conference Abstracts

Scott C; Lee CK; Lee YC; Friedlander M; Hollis S; Diamante K; Davies C; Stockler M; Plebanski M, 2019, 'SOLACE2: A phase II randomised trial of immune priming by olaparib-cyclophosphamide prior to olaparib-durvalumab in asymptomatic, platinum-sensitive recurrent ovarian cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 15, pp. 160 - 161, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000493438400250&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Dieras VC; Han HS; Kaufman B; Wildiers H; Friedlander M; Ayoub J-P; Puhalla SL; Bondarenko I; Campone M; Jakobsen EH; Jalving M; Oprean C; Palacova M; Park YH; Shparyk Y; Yanez E; Dudley M; Ratajczak CK; Maag D; Arun BK, 2019, 'Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Barcelona, Vol. 30, pp. 857 - +, presented at 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 27 September 2019 - 01 October 2019

Oaknin A; Moore K; Colombo N; Scambia G; Kim B-G; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza AM; Gonzalez-Martin A; Aghajanian C; Bradley W; Lowe ES; Bloomfield R; DiSilvestro P, 2019, 'Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): Phase III SOLO1 trial', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Barcelona, Vol. 30, pp. 405 - 405, presented at 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 27 September 2019 - 01 October 2019

Kok PS; Yoon W-H; Marschner I; Lord SJ; Friedlander M; Lee CK, 2019, 'Validation of progression-free survival (PFS) as surrogate endpoint in randomised trials of immune checkpoint inhibitors in advanced solid cancers', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Barcelona, Vol. 30, pp. 520 - 520, presented at 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 27 September 2019 - 01 October 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000491295503324&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Coleman RL; Fleming GF; Brady MF; Swisher E; Steffensen KD; Friedlander M; Okamoto A; Moore K; Ben-Baruch N; Werner TL; Oaknin A; Nam J-H; Leath CA; Nicum S; Cella D; Sullivan DM; Ansell PJ; Dinh M; Aghajanian C; Bookman MA, 2019, 'VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Barcelona, Vol. 30, pp. 895 - 896, presented at 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 27 September 2019 - 01 October 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000491295500127&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Desai J; Markman B; Friedlander M; Gan H; Horvath L; Townsend A; Millward M; Jameson M; Yen C-J; Hou M-M; Hou J; Wu J; Liang L; Deva S, 2019, 'Abstract CT084: Long-term exposure (LTE) to Tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human Phase I study', in Cancer Research, American Association for Cancer Research (AACR), Vol. 79, pp. ct084 - ct084, http://dx.doi.org/10.1158/1538-7445.am2019-ct084

Roncolato F; O'Connell R; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Pignata S; Donnellan PP; Oza AM; Avall-Lundqvist E; Berek JS; Sehouli J; Ledermann JA; Berton-Rigaud D; Kiely BE; Friedlander M; Stockler MR, 2019, 'How long have we got? The accuracy of physicians' estimates and scenarios for survival time in 898 women with recurrent ovarian cancer (ROC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 37, presented at 55th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.5549

Antill YC; Kok PS; Robledo K; Barnes E; Friedlander M; Baron-Hay SE; Shannon CM; Coward J; Beale PJ; Goss G; Meniawy T; Yip S; Smith D; Spurdle AB; Parry M; Andrews J; Kelly M; Stockler MR; Mileshkin LR, 2019, 'Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 37, pp. 5501 - 5501, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.5501

Colombo N; Moore KN; Scambia G; Oaknin A; Friedlander M; Lisyanskaya AS; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee SN; Oza AM; González-Martín A; Aghajanian C; Bradley WH; Kim J-W; Lowe ES; Bloomfield R; Disilvestro P, 2019, 'Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Phase III SOLO1 trial.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 37, pp. 5539 - 5539, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.5539

Friedlander M; Moore KN; Colombo N; Scambia G; Kim B-G; Oaknin A; Lisyanskaya AS; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee SN; Oza AM; González-Martín A; Aghajanian C; Bradley WH; Lowe ES; Bloomfield R; Disilvestro P, 2019, 'Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 37, pp. 5551 - 5551, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.5551

Mathews CA; Moore KN; Colombo N; Scambia G; Kim B-G; Oaknin A; Friedlander M; Lisyanskaya AS; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee SN; Oza AM; González-Martín A; Aghajanian C; Bradley WH; Lowe ES; Bloomfield R; Disilvestro P, 2019, 'Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Efficacy by surgical and tumor status in the Phase III SOLO1 trial.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 37, pp. 5541 - 5541, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.5541

Friedlander ML; Moore KN; Colombo N; Scambia G; Kim B-G; Oaknin A; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley W; Lowe E; Hettle R; Flood E; Disilvestro P, 2019, '224O Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)', in Annals of Oncology, Elsevier, Vol. 30, pp. ix77, http://dx.doi.org/10.1093/annonc/mdz426

Poveda A; Sackeyfio A; Friedlander M, 2019, '321 Maintenance olaparib for BRCA-mutated ovarian cancer (OC) patients in 1st line and platinum-sensitive relapsed (PSR) settings: maximizing treatment opportunities', in International Journal of Gynecological Cancer, Elsevier, Vol. 29, pp. a133, http://dx.doi.org/10.1136/ijgc-2019-igcs.321

Peate M; Jayasinghe Y; Gamage NR; Allingham C; Meiser B; Friedlander M; Hickey M, 2018, 'From development to implementation: The Australian experience of oncofertility decision aids', in PSYCHO-ONCOLOGY, WILEY, Vol. 27, pp. 44 - 45, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000448188000113&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Peate M; Patterson T; Girgis A; Friedlander M; Durcinoska I; Hickey M; Sousa MS, 2018, 'Genitourinary and sexual health after breast cancer: The role of breast care nurses in providing support and care', in PSYCHO-ONCOLOGY, WILEY, Vol. 27, pp. 184 - 185, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000448188000492&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Oza AM; Cibula D; Oaknin A; Poole C; Mathijssen RHJ; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Pfisterer J; Plante M; Hanker LC; Fielding A; Haddad V; Chmielecki J; Friedlander M, 2018, 'Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy', in Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii340, http://dx.doi.org/10.1093/annonc/mdy285.158

Beesley VL; Webber K; Nagle C; Grant P; DeFazio A; Obermair A; Friedlander M; Webb PM, 2018, 'When will i feel normal again? Exploring the trajectories and predictors of patient-reported outcomes after completion of primary therapy for ovarian cancer', in PSYCHO-ONCOLOGY, WILEY, Vol. 27, pp. 50 - 50, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000448188000128&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Piskorz A; Robertson D; Lin KK; Morris J; Mann E; Oza A; Coleman RL; O'Malley DM; Friedlander M; Cragun JM; Ma L; Giordano H; McNeish IA; Swisher E; Wason J; Brenton JD, 2018, 'CTDNA RESPONSE TO THE PARP INHIBITOR RUCAPARIB PREDICTS PROGRESSION-FREE SURVIVAL AND BEST OVERALL RESPONSE ON THE ARIEL2 TRIAL', in CLINICAL CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, WA, Seattle, Vol. 25, pp. 112 - 112, presented at 12th Rivkin-Centre Biennial Ovarian Cancer Research Symposium, WA, Seattle, 13 September 2018 - 15 September 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000497337700065&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Friedlander M; Scott CL; Lindeman GJ; Gibbs E; Badger HD; Paterson RJ; Macnab L; Zdenkowski N; Kwan EM; Boyle FM; Lee CK, 2018, 'A Phase 1 Trial of Olaparib and Oral Metronomic. Cyclophosphamide in Patients with Metastatic BRCA-Associated Breast/Ovarian Cancers or Non-BRCA Associated Triple-Negative Breast Cancer/High Grade Serous Ovarian Cancers', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 14, pp. 59 - 59, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000439493100024&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Friedlander M; Meniawy T; Markman B; Mileshkin LR; Harnett P; Millward M; Lundy J; Freimund AE; Norris C; Wu J; Paton V; Wang L; Gao B, 2018, 'A Phase 1B Study of the Anti-PD-1 Monoclonal Antibody, Tislelizumab, in Combination with the Parp Inhibitor, Pamiparib, in Advanced Solid Tumors', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 14, pp. 58 - 59, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000439493100023&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hasenburg A; Harter P; Park-Simon T-W; Gropp-Meier M; Heitz F; Soergel P; Ataseven B; Friedlaender M; Hilpert F; Pujade-Lauraine E, 2018, 'Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer: SOLO2 Phase III', in ONCOLOGY RESEARCH AND TREATMENT, KARGER, Vol. 41, pp. 88 - 89, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000424914300235&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Sackeyfio A; Santi I; Friedlander M, 2018, 'PCN347 - EXPLORING THE IMPACT OF RADIOGRAPHIC PROGRESSIVE DISEASE AND FIRST SUBSEQUENT THERAPY ON HEALTH STATE UTILITY VALUES IN GERMLINE-BRCA-MUTATED (GBRCAM) PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER (PSROC) PATIENTS ON OLAPARIB TABLETS AS MAINTENANCE MONOTHERAPY', in Value in Health, Elsevier, Vol. 21, pp. s73, http://dx.doi.org/10.1016/j.jval.2018.09.429

Friedlander M; Gourley C; Matulonis U; Shirinkin V; Selle F; Scott C; Safra T; Fielding A; Rowe P; Ledermann JA, 2017, 'CLINICALLY SIGNIFICANT LONG-TERM MAINTENANCE TREATMENT WITH OLAPARIB IN PATIENTS WITH PLATINUM-SENSITIVE RELAPSED SEROUS OVARIAN CANCER (PSR SOC)', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, Vol. 27, pp. 1942 - 1943, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000423235205226&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Friedlander M; Gebski V; Gibbs E; Bloomfield R; Hilpert F; Wenzel LB; Joly F; Eek D; Rodrigues M; Clamp A; Penson R; Provencher D; Korach J; Huzarski T; Vidal L; Salutari V; Scott C; Nicoletto MO; Tamura K; Pujade-Lauraine E, 2017, 'HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND PATIENT-CENTRED OUTCOMES WITH OLAPARIB MAINTENANCE POST-CHEMOTHERAPY IN PATIENTS WITH GERMLINE BRCA-MUTATED PLATINUM-SENSITIVE RELAPSED SEROUS OVARIAN CANCER (PSR SOC)', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, Vol. 27, pp. 1941 - 1941, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000423235205225&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Meagher NS; deFazio A; Russell K; Voss A; Ramus SJ; Friedlander ML, 2017, 'Mucinous Ovarian Cancers of Uncertain Primary (MO-CUP) - Does the Site of Origin Really Matter?', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 13, pp. 73 - 73, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000413954500039&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hettle R; Sackeyfio A; Gill J; Siddiqui K; Nussey F; Friedlander M, 2017, 'COMPARATIVE EFFICACY AND SAFETY OF OLAPARIB 300 MG TABLETS BID AND NIRAPARIB 300 MG TABLETS QD AS MAINTENANCE TREATMENT AFTER RESPONSE TO CHEMOTHERAPY IN PATIENTS WITH PLATINUM-SENSITIVE RELAPSED GERMLINE BRCA-MUTATED OVARIAN CANCER (PSROC)', in VALUE IN HEALTH, ELSEVIER SCIENCE INC, Vol. 20, pp. A412 - A412, http://dx.doi.org/10.1016/j.jval.2017.08.088

Sackeyfio A; Gill J; Hettle R; Siddiqui K; Friedlander M; Ledermann JA, 2017, 'COMPARATIVE EFFICACY AND SAFETY OF OLAPARIB 400 MG CAPSULES BID AND NIRAPARIB 300 MG TABLETS QD AS MAINTENANCE TREATMENT AFTER RESPONSE TO CHEMOTHERAPY IN PATIENTS WITH PLATINUM-SENSITIVE RELAPSED NON-GERMLINE BRCA-MUTATED OVARIAN CANCER (PSROC)', in VALUE IN HEALTH, ELSEVIER SCIENCE INC, Vol. 20, pp. A412 - A412, http://dx.doi.org/10.1016/j.jval.2017.08.087

Webber K; Girgis A; Kaye B; Bonaventura BA; Boyle FM; Koh E-S; Friedlander M; Segelov E; Goldstein D, 2013, 'The unmet needs of cancer survivors and their preferences for discussing them with oncologists and general practitioners (GPs)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 31, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419603085&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Webber K; Girgis A; Bennett BK; Bonaventura T; Boyle F; Koh E-S; Friedlander M; Segelov E; Goldstein D, 2012, 'CURRENT CARE AND NEEDS OF ADULT CANCER SURVIVORS - A CROSS-SECTIONAL SURVEY', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, Vol. 8, pp. 356 - 357, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000310544400419&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mok K; Mireskandari S; Juraskova I; Jarvis S; Friedlander M, 2006, 'OVER (Olive oil Vaginal Exercises and Replens) come', in PSYCHO-ONCOLOGY, WILEY-BLACKWELL, Vol. 15, pp. S332 - S332, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000242413901224&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Tiller K; Meiser B; Tucker K; Andrews L; Gaff C; Kirk J; Phillips KA; Duding T; Friedlander M, 2003, 'A randomised trial of a decision aid for women at risk for ovarian cancer', in PSYCHO-ONCOLOGY, JOHN WILEY & SONS LTD, Vol. 12, pp. S107 - S107, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000183225400100&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Back to profile page